Prostate cancer screening among elderly men in Brazil: should we diagnose or not?
Int. braz. j. urol; 46 (1), 2020
Publication year: 2020
ABSTRACT Purpose:
Prostate cancer screening in the elderly is controversial. The Brazilian government and the National Cancer Institute (INCA) do not recommend systematic screening. Our purpose was to assess prevalence and aggressiveness of prostate cancer in men aged 70 years and above, on the first Latin American database to date.Materials and Methods:
Cross-sectional study (n=17,571) from 231 municipalities, visited by Mobile Cancer Prevention Units of a prostate-specific antigen (PSA) based opportunistic screening program, between 2004 and 2007.The criteria for biopsy were:
PSA>4.0ng/ml, or PSA 2.5-4.0ng/ml with free/total PSA ratio ≤15%, or suspicious digital rectal examination findings. The screened men were stratified in two age groups (45-69 years, and ≥70 years). These groups were compared regarding prostate cancer prevalence and aggressiveness criteria (PSA, Gleason score from biopsy and TNM staging).Results:
The prevalence of prostate cancer found was 3.7%. When compared to men aged 45-69 years, individuals aged 70 years and above presented cancer prevalence about three times higher (prevalence ratio 2.9, p<0.01), and greater likelihood to present PSA level above 10.0ng/ml at diagnosis (odds ratio 2.63, p<0.01). The group of elderly men also presented prevalence of histologically aggressive disease (Gleason 8-10) 3.6 times higher (p<0.01), and 5-fold greater prevalence of metastases (PR 4.95, p<0.05).Conclusions:
Prostate cancer screening in men aged over 70 may be relevant in Brazil, considering the absence of systematic screening, higher prevalence and higher probability of high-risk disease found in this age range of the population studied.
Factores de Edad, Biopsia, Brasil/epidemiología, Estudios Transversales, Tacto Rectal, Detección Precoz del Cáncer, Tamizaje Masivo/métodos, Persona de Mediana Edad, Clasificación del Tumor, Estadificación de Neoplasias, Prevalencia, Antígeno Prostático Específico/sangre, Neoplasias de la Próstata/diagnóstico, Neoplasias de la Próstata/epidemiología, Neoplasias de la Próstata/patología, Medición de Riesgo, Factores de Riesgo